First patient dosed in AB101 Phase 1 clinical study
AB101 Phase 1 IND application filed with U.S. FDA and initiated Phase 1 clinical study
Series B tranche 1, 2, and 3 funding (KRW 30 bn) completed
pH Pharma Co., Ltd. became the majority shareholder of AntriaBio Inc.
Contract signed with Bayer to acquire BAY85-8501 (DBA "PHP-303")
Launched Tria cosmetics with skin care line and mask pack
MFDS approved PHP-201 Phase 2 clinical trial initiation in Korea
PHP-201 IND filed with MFDS to begin Phase 2B trials in Korea in normal tension glaucoma
Acquisition of Poly Remedy Inc (DBA "Nuvesse Skin Therapies, Inc.")
with its IPs (patented Cellulation Technology™)
Tria transition completed and the first revenue booked at PHP
AB101 FDA meeting to finalize Phase 1 trial design and development plan in D.C.
PHP-201 asset transfer completed
Contract signed with Tria Beauty Inc.
1st round of funding (KRW 9.0 bn) from SBI & Magna completed
Contract signed with AntriaBio Inc.
Investment from employees and angels completed (KRW 3.1 bn)
pH Pharma Inc. established at Palo Alto, CA
Contract signed with Amakem Therapeutics NV to Acquire AMA0076 (DBA "PHP-201")
pH Pharma Co., Ltd. established in Seoul, Korea
pH Pharma Co., Ltd. incubation started
Pipeline assets due diligence began
© COPYRIGHT 2017. ALL RIGHTS RESERVED.